Janney Montgomery Scott LLC raised its stake in shares of Fresenius Medical Care Corporation (NYSE:FMS) by 7.1% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 21,375 shares of the company’s stock after buying an additional 1,423 shares during the period. Janney Montgomery Scott LLC’s holdings in Fresenius Medical Care Corporation were worth $1,033,000 at the end of the most recent reporting period.

Several other institutional investors have also made changes to their positions in FMS. Level Four Advisory Services LLC increased its position in shares of Fresenius Medical Care Corporation by 0.5% in the first quarter. Level Four Advisory Services LLC now owns 11,434 shares of the company’s stock valued at $478,000 after buying an additional 58 shares during the last quarter. Intrust Bank NA increased its position in shares of Fresenius Medical Care Corporation by 0.8% in the first quarter. Intrust Bank NA now owns 13,219 shares of the company’s stock valued at $557,000 after buying an additional 99 shares during the last quarter. Greenleaf Trust increased its position in shares of Fresenius Medical Care Corporation by 2.6% in the second quarter. Greenleaf Trust now owns 4,992 shares of the company’s stock valued at $241,000 after buying an additional 126 shares during the last quarter. Wrapmanager Inc. increased its position in shares of Fresenius Medical Care Corporation by 3.5% in the first quarter. Wrapmanager Inc. now owns 7,222 shares of the company’s stock valued at $304,000 after buying an additional 244 shares during the last quarter. Finally, NGAM Advisors L.P. increased its position in shares of Fresenius Medical Care Corporation by 0.8% in the second quarter. NGAM Advisors L.P. now owns 43,614 shares of the company’s stock valued at $2,108,000 after buying an additional 338 shares during the last quarter. Institutional investors and hedge funds own 2.84% of the company’s stock.

Shares of Fresenius Medical Care Corporation (NYSE FMS) opened at 45.85 on Friday. The firm’s 50-day moving average price is $47.66 and its 200 day moving average price is $44.76. Fresenius Medical Care Corporation has a 52 week low of $38.05 and a 52 week high of $50.22. The company has a market capitalization of $28.14 billion, a PE ratio of 20.02 and a beta of 0.47.

Fresenius Medical Care Corporation (NYSE:FMS) last released its earnings results on Tuesday, August 1st. The company reported $0.48 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.53 by $0.05. Fresenius Medical Care Corporation had a return on equity of 11.57% and a net margin of 7.06%. The business had revenue of $4.47 billion during the quarter, compared to analysts’ expectations of $5.20 billion. During the same period last year, the business earned $0.96 earnings per share. The company’s revenue for the quarter was up 11.1% compared to the same quarter last year. Equities analysts predict that Fresenius Medical Care Corporation will post $2.33 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “Fresenius Medical Care Corporation (FMS) Shares Bought by Janney Montgomery Scott LLC” was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece of content on another publication, it was stolen and republished in violation of international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.thecerbatgem.com/2017/08/13/fresenius-medical-care-corporation-fms-shares-bought-by-janney-montgomery-scott-llc.html.

Several brokerages have recently commented on FMS. UBS AG restated a “sell” rating on shares of Fresenius Medical Care Corporation in a research report on Tuesday, July 4th. DZ Bank AG reaffirmed a “neutral” rating on shares of Fresenius Medical Care Corporation in a report on Thursday, May 11th. Royal Bank Of Canada reaffirmed a “hold” rating and issued a $44.00 target price on shares of Fresenius Medical Care Corporation in a report on Wednesday, July 5th. BidaskClub cut Fresenius Medical Care Corporation from a “buy” rating to a “hold” rating in a report on Monday, July 31st. Finally, Zacks Investment Research raised Fresenius Medical Care Corporation from a “hold” rating to a “buy” rating and set a $54.00 target price on the stock in a report on Tuesday, July 11th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and eight have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $48.67.

About Fresenius Medical Care Corporation

Fresenius Medical Care AG & Co KGaA is a kidney dialysis company. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD), as well as other healthcare services. The Company’s segments include North America Segment, the Europe, Middle East and Africa (EMEA) Segment, the Asia-Pacific Segment and the Latin America Segment.

Want to see what other hedge funds are holding FMS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Fresenius Medical Care Corporation (NYSE:FMS).

Institutional Ownership by Quarter for Fresenius Medical Care Corporation (NYSE:FMS)

Receive News & Stock Ratings for Fresenius Medical Care Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care Corporation and related stocks with our FREE daily email newsletter.